Sign in
CompletedNo phase

Women's Opioid Treatment Follow-up Study

Key facts

Who runs it
Mclean Hospital
Where
Belmont, United StatesSee the site
Trial code
Status
Completed
People taking part
39 people enrolled
Started
8 Mar 2024
Ended
16 Oct 2025
Type of study
Interventional, 2 groups
Treatments tested
  • Gender-specific digital intervention (GSDI)
  • Treatment as usual
Record updated
13 April 2026

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part
Show the full registry criteria (7)Hide the full registry criteria

Who can take part

  • age 18 years of age or older
  • current opioid use disorder diagnosis
  • have a smartphone
  • initiated medication treatment for opioid use disorder in the past 30 days,
  • able to provide informed consent

Who cannot take part

  • an acute psychiatric or medical condition, or cognitive impairment, that would impair the ability to complete study procedures
  • admitted to their current treatment episode on an involuntary status

Where in United States

  • McLean HospitalBelmont, United States

About the trial

What the trial wants to find out

The goal of this study is to examine the feasibility of a gender-specific digital intervention for women with opioid use disorder. In this study, women with opioid use disorder will be randomized to receive treatment-as-usual plus a gender-specific digital intervention or treatment-as-usual only. Feasibility, satisfaction, and engagement with the intervention are the primary outcomes and will be measured post-intervention and at two-week, 6-week, and 12-week follow-up visits.

The 2 groups in the trial

  • Gender-specific digital intervention plus treatment as usual (GSDI+TAU)Treatment being tested

    GSDI + TAU includes the addition of a gender-specific digital intervention (GSDI) to treatment as usual. The GSDI has a web-based component and a mobile component. The web-based portion of the GSDI includes: (1) gender-specific psychoeducation on substance use disorders, (2) specific education on opioid use disorder, including information about medication treatment for opioid use disorder, and (3) information on relapse-prevention skills. Participants complete the web-based portion immediately after completing baseline assessments. The mobile component includes three parts: (1) weekly self-report surveys of opioid and other substance use and medication adherence, (2) weekly skills-practice exercises, and (3) daily motivational messages encouraging self-care. Participants engage with the mobile component after completing the web-based portion until the end of the study (12 weeks).

    Treatment: Gender-specific digital intervention (GSDI) and Treatment as usual

  • Treatment as usual (TAU)Other group

    TAU for opioid use disorder consists of a mix of medication treatment and individual and group therapy services across various levels of care: inpatient, residential, and outpatient. Residential treatment is for adults who have completed detoxification and require additional treatment in a structured environment. Inpatient treatment includes short-term care and detoxification treatment and incorporates a combination of group, family, and individual therapy targeted at medical stabilization, reducing the severity of the patient's symptoms, and providing resources and ongoing support to prevent relapse. Outpatient treatment is focused on comprehensive evaluation and stabilization.

    Treatment: Treatment as usual

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Increasing Women's Engagement in Medication Treatment for Opioid Use Disorder Through Digital Intervention
Record updated
13 April 2026